Drug Profile

G 012

Alternative Names: FGFR3 (SM); FGFR3 modulating therapeutic - Onco3R therapeutics; G-012

Latest Information Update: 02 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Galapagos NV
Developer Onco3R Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Type 3 fibroblast growth factor receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer; Immunological disorders

Most Recent Events

22 Oct 2025 Pharmacodynamics data from a preclinical study in Cancer released by Onco3R Therapeutics
22 Oct 2025 Onco3R therapeutics announced their plans to initiate IND-enabling studies for cancer in 2026
18 Aug 2025 Preclinical trials in Cancer in Belgium (unspecified route) prior to August 2025 (Onco3R therapeutics pipeline, August 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com